

Most Read This Week
- Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- [177Lu]Lu-PSMA-617 vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
- Circulating Tumour DNA in Patients With Advanced Melanoma Treated With Dabrafenib or Dabrafenib Plus Trametinib
- ASCO GU 2021: Talazoparib Demonstrates Durable Antitumor Activity in Metastatic Castration-Resistant Prostate Cancer
- Cobimetinib + Chemotherapy ± Atezolizumab as First-Line Treatment for Locally Advanced or Metastatic Triple-Negative Breast Cancer
Recently Updated
- Outcomes of Subsegmental Pulmonary Embolism in Cancer Patients
- Impact of Treatment Type on Survival of Breast Cancer in Women With a BRCA2 Mutation
- Endoscopic Surgery vs Intensity-Modulated Radiotherapy in Resectable Locally Recurrent Nasopharyngeal Carcinoma
- Zolbetuximab Plus EOX vs EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma
- Predicted Sensitivity to Endocrine Therapy for Stage II–III HR-Positive and HER2-Negative Breast Cancer